Mangostana Llc | |
1020 Coal Ave Se, Albuquerque, NM 87106-5206 | |
(505) 221-6475 | |
Not Available |
Full Name | Mangostana Llc |
---|---|
Type | Facility |
Speciality | Clinic/center - Physical Therapy |
Location | 1020 Coal Ave Se, Albuquerque, New Mexico |
Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1033991443 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
225100000X | Physical Therapist | (* (Not Available)) | Secondary |
261QP2000X | Clinic/center - Physical Therapy | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mangostana Llc 6804 Kelly Ann Rd Ne, Albuquerque, NM 87109-3769 Ph: (505) 221-6475 | Mangostana Llc 1020 Coal Ave Se, Albuquerque, NM 87106-5206 Ph: (505) 221-6475 |
News Archive
Eclipsys Corporation, The Outcomes Company®, today announced results for the first quarter ended March 31, 2010.
Lung function pathology takes in some 200 diseases which have much radiological and pathological data in common, and which can greatly shorten the life of the patient, the last resort being a lung transplant.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that although platinum-based treatment will continue to be the standard of care for first- and second-line treatment of platinum-sensitive ovarian cancer, pegylated liposomal doxorubicin (PLD)/carboplatin will replace paclitaxel/carboplatin as the standard second-line treatment for patients who remain platinum sensitive.
Facebook use linked to perceptions of worsening physical health, new research from the University of Surrey, reports.
› Verified 9 days ago